0 0
    • Mark all read All chats All chats
    Finabase
    • Categories
    • Register
    • Login
    Home Watchlists Portfolios Map Forex Futures Crypto Comparisons Alerts Screeners Backtests vTrading Settings Forum
    1. Home
    2. ISEE
    • Alert
    • Note
    -
    x
    x
    bid
    ask
    04:01 AM
    Bearish 3
    Bullish 25
    sentiment
    day range
    52 week range
    04:01 AM
    V: 0.00
    C:
    L:
    H:
    O:
    loading chart ...
    • 1d
    • 5d
    • 1m
    • 3m
    • 6m
    • ytd
    • 1y
    • 2y
    • 5y
    • max
    • PDF
    • Full Chart
    • Stats
    • Watchlist
    • Portfolio
    Prev Close
    Open
    Low
    High
    Volume0.00
    Avg. Volume0.00
    Market Cap0.00
    Inst. Own
    Beta
    Short Ratio
    Div & Yield /
    EPS
    P/E
    1yr Target
    50day MA
    200day MA
    ^DJI
    Dow Jones Industrial Average
    33963.80
    05:35 PM
    -
    106.60
    0.31%
    ^IXIC
    NASDAQ Composite
    13211.80
    05:15 PM
    -
    12.20
    0.09%
    ^GSPC
    S&P 500
    4320.06
    05:35 PM
    -
    9.94
    0.23%
    AAPL
    174.95
    +0.16 (0.09%)
    Apple Inc.
    174.79
    9 @ 04:00 PM
    9 x 174.93
    9 x 175.10
    +
    0.86
    0.49%
    GOOG
    131.44
    +0.19 (0.15%)
    Alphabet Inc.
    131.25
    9 @ 04:00 PM
    8 x 131.50
    9 x 131.63
    -
    0.11
    0.08%
    AMZN
    129.30
    +0.18 (0.14%)
    Amazon.com, Inc.
    129.12
    9 @ 04:00 PM
    8 x 129.27
    10 x 129.28
    -
    0.21
    0.16%
    MSFT
    316.81
    -0.20 (0.06%)
    Microsoft Corporation
    317.01
    11 @ 04:00 PM
    8 x 316.81
    13 x 317.01
    -
    2.52
    0.79%
    BABA
    88.50
    +0.20 (0.23%)
    Alibaba Group Holding Limited
    88.30
    8 @ 04:01 PM
    8 x 88.50
    8 x 88.58
    +
    4.19
    4.98%
    NFLX
    379.65
    -0.16 (0.04%)
    Netflix, Inc.
    379.81
    10 @ 04:00 PM
    9 x 379.82
    11 x 380.43
    -
    4.34
    1.13%
    TSLA
    244.16
    -0.72 (0.29%)
    Tesla, Inc.
    244.88
    11 @ 04:00 PM
    9 x 243.86
    13 x 244.16
    -
    10.82
    4.23%
    NVDA
    415.74
    -0.36 (0.09%)
    NVIDIA Corporation
    416.10
    21 @ 04:00 PM
    11 x 415.58
    31 x 415.90
    +
    5.93
    1.45%
    AMD
    96.08
    -0.12 (0.12%)
    Advanced Micro Devices, Inc.
    96.20
    13 @ 04:00 PM
    14 x 96.01
    12 x 96.13
    +
    0.09
    0.09%
    MU
    68.89
    +0.01 (0.01%)
    Micron Technology, Inc.
    68.88
    14 @ 04:00 PM
    14 x 68.85
    13 x 68.95
    +
    0.98
    1.44%
    SPY
    430.69
    +0.27 (0.06%)
    SPDR S&P 500 ETF Trust
    430.42
    31 @ 04:00 PM
    31 x 430.52
    30 x 430.80
    -
    0.97
    0.22%
    TQQQ
    35.68
    +0.05 (0.15%)
    ProShares UltraPro QQQ
    35.63
    35 @ 04:00 PM
    40 x 35.68
    29 x 35.73
    +
    0.02
    0.07%
    BRK-A
    544000.00
    -2215.00 (0.41%)
    Berkshire Hathaway Inc.
    546215.00
    10 @ 04:00 PM
    9 x 544500.00
    10 x 547042.00
    -
    4815.00
    0.87%
    Day Gain
    Gain
    Market Val
    Costs
    Cash
    Portfolio
    Realized
    Dividend
    • Summary
    • Discussion
    • News
    • Signals
    • Financials
    • Alerts
    • Notes
    • Chart
    • Backtest
    News ...
    Deep Track Capital, LP Acquires New Stake in Terns Pharmaceuticals Inc gurufocus.com •
    Astellas Pharma CEO Says Confident of Iveric Bio Drug Approval youtube.com •
    Iveric Bio stock surges on Astellas Pharma takeover deal proactiveinvestors.com •
    Biotech Buying Bonanza: Iveric Bio Snags $5.9 Billion Deal From Astellas Pharma investors.com •
    Iveric Bio Stock Surges. It's Being Bought by Astellas for $5.9 Billion. barrons.com •
    Japan's Astellas Pharma to buy Iveric Bio in deal worth $5.9 billion marketwatch.com •
    Profile ...
    IVERIC bio, Inc., a biopharmaceutical company, focuses on the discovery and development of novel treatments for retinal diseases with unmet medical needs. The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD); and STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of autosomal recessive Stargardt disease. Its preclinical product candidatures include IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases. The company also develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of avacincaptad pegol (ACP) administered as a monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of ACP administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. In addition, its minigene programs comprises miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related inherited retinal diseases (IRDs). The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey. As of July 11, 2023, IVERIC bio, Inc. operates as a subsidiary of Astellas US Holding, Inc.
    Earning ...
    Date For Estimate Reported Surprise surprise %
    2023-07-25 2023-06 -0.49 N/A N/A N/A
    2023-05-10 2023-03 -0.44 N/A N/A N/A
    2023-03-01 2022-12 -0.37 N/A N/A N/A
    2022-11-03 2022-09 -0.4 N/A N/A N/A
    2022-07-26 2022-06 -0.31 N/A N/A N/A
    2022-05-04 2022-03 -0.29 N/A N/A N/A
    Upgrade / Downgrade ...
    Date Firm Action From To
    2023-05-08 TD Cowen Downgrade Outperform Market Perform
    2023-05-04 Baird Downgrade Outperform Neutral
    2023-05-03 UBS Downgrade Buy Neutral
    2023-05-02 HC Wainwright & Co. Downgrade Buy Neutral
    2023-05-01 Wedbush Downgrade Outperform Neutral
    2023-05-01 Guggenheim Downgrade Buy Neutral
    Insider Holder ...
    Date Name Relation Quantity Description
    2023-05-10 BLUMENKRANZ MARK S Director 32.09K Conversion of Exercise of derivative security
    2023-05-10 BOLTE AXEL Director 22.09K Conversion of Exercise of derivative security
    2023-06-25 CARROLL DAVID FRANCIS Chief Financial Officer 44.15K Stock Gift
    2023-06-27 GIBNEY ANTHONY S. Officer 40.29K Stock Gift
    2023-05-10 GRAVES ADRIENNE L Director 22.09K Conversion of Exercise of derivative security
    2023-05-10 HENDERSON JANE Director 22.09K Conversion of Exercise of derivative security
    Institution Ownership ...
    Report Date Organization Position Value Percentage
    2023-03-30 Vanguard Group, Inc. (The) 13.66M 545.77M 9.92%
    2023-03-30 Blackrock Inc. 10.13M 404.63M 7.35%
    2023-03-30 Price (T.Rowe) Associates Inc 6.81M 272.17M 4.94%
    2023-03-30 Avoro Capital Advisors LLC 6.80M 271.66M 4.94%
    2023-03-30 Deep Track Capital, LP 6.50M 259.68M 4.72%
    2023-03-30 State Street Corporation 5.62M 224.69M 4.08%
    Fund Ownership ...
    Report Date Organization Position Value Percentage
    2022-12-30 Vanguard Total Stock Market Index Fund 4.06M 162.20M 2.96%
    2023-02-27 SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF 3.38M 135.05M 2.47%
    2023-02-27 iShares Russell 2000 ETF 2.96M 118.24M 2.16%
    2022-12-30 Smallcap World Fund 2.16M 86.46M 1.58%
    2022-12-30 Price (T.Rowe) Health Sciences Fund 1.84M 73.33M 1.34%
    2022-12-30 Vanguard Small-Cap Index Fund 1.73M 69.04M 1.26%
      • Oldest to Newest
      • Newest to Oldest
      • Most Votes
    • 1 / 1
    Reply
    • Reply as topic
    Log in to reply
    This topic has been deleted. Only users with topic management privileges can see it.
    • C Offline
      C Offline
      csrqf84t9y | Only
      wrote on Sep 9 - last edited by
      #1

      Take profits and head too $OCGN for there eye and Vaxx run next…

      1 Reply Last reply
      0
    • E Offline
      E Offline
      evelliquette | Only
      wrote on Sep 6 - last edited by
      #2

      $ISEE me shorting this one……it’s going down

      1 Reply Last reply
      0
    • H Offline
      H Offline
      hu7rb5jzei | Only
      wrote on Sep 1 - last edited by
      #3

      Only the big dogs know. Us retail slobs have to guess on the up one no news.

      1 Reply Last reply
      0
    • H Offline
      H Offline
      hu7rb5jzei | Only
      wrote on Sep 1 - last edited by
      #4

      Good luck on the cash secured puts. I hope you don’t get burned. Almost too good to be true.

      1 Reply Last reply
      0
    • H Offline
      H Offline
      hu7rb5jzei | Only
      wrote on Aug 31 - last edited by
      #5

      Something is Brewing.

      1 Reply Last reply
      0
    • H Offline
      H Offline
      hu7rb5jzei | Only
      wrote on Aug 29 - last edited by
      #6

      Will it touch 11 or 9 first?

      1 Reply Last reply
      0
    • H Offline
      H Offline
      hu7rb5jzei | Only
      wrote on Aug 25 - last edited by
      #7

      Why is this selling off so hard?

      1 Reply Last reply
      0
    • D Offline
      D Offline
      dcschaap | Only
      wrote on Jun 18 - last edited by
      #8

      $ISEE you at $10!

      1 Reply Last reply
      0
    • M Offline
      M Offline
      maynall44 | Only
      wrote on May 11 - last edited by
      #9

      $OBSV: Surprise earning by 113% above est $16-$37
      .
      $CAPR : Covid-19 Play...News coming this month 14th

      $MARK : Still time to get in under $4 very under value.

      1 Reply Last reply
      0
    • 1 / 1
    • Deep Track Capital, LP Acquires New Stake in Terns Pharmaceuticals Inc
      gurufocus.com •

    • Astellas Pharma CEO Says Confident of Iveric Bio Drug Approval
      youtube.com •

    • Iveric Bio stock surges on Astellas Pharma takeover deal
      proactiveinvestors.com •

    • Biotech Buying Bonanza: Iveric Bio Snags $5.9 Billion Deal From Astellas Pharma
      investors.com •

    • Iveric Bio Stock Surges. It's Being Bought by Astellas for $5.9 Billion.
      barrons.com •

    • Japan's Astellas Pharma to buy Iveric Bio in deal worth $5.9 billion
      marketwatch.com •

    • These Are the Top 10 Holdings of David Kim
      247wallst.com •

    • Why Is Iveric Bio (ISEE) Stock Up 25% Today?
      investorplace.com •

    • IVERIC bio, Inc. (ISEE) Q3 2022 Earnings Call Transcript
      seekingalpha.com •

    • Iveric Bio to Present at Upcoming Investor Conferences
      businesswire.com •

    • Apellis Pharma Crashes On Unexpected Delay For Eye Drug — A Boon For Iveric Bio
      investors.com •

    • These Were The Five Best And Worst Performing Mid-Cap Stocks In September 2022
      247wallst.com •

    • Iveric Bio to Present Top-line Results for Avacincaptad Pegol from Phase 3 GATHER2 Clinical Trial in Geographic Atrophy at AAO 2022 Annual Meeting
      businesswire.com •

    • IVERIC bio (ISEE) Posts Positive Top-Line Data From GA Study
      zacks.com •

    • Iveric bio: Further Upside Possible Based On Expanded Opportunities With Zimura
      seekingalpha.com •

    • Why Is Iveric Bio (ISEE) Stock Up 56% Today?
      investorplace.com •

    • 7 Cheap Biotech Stocks to Buy Now
      investorplace.com •

    • IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q2 2022 Results - Earnings Call Transcript
      seekingalpha.com •

    • Iveric Bio to Report Second Quarter 2022 Financial Results and Host Conference Call on Tuesday, July 26, 2022
      businesswire.com •

    • Trial Results Set to Make or Break Small-Cap Pharma Stocks
      gurufocus.com •

    • IVERIC bio: A First Take
      seekingalpha.com •

    • Biopharmaceutical Stocks: The Bottoming Process Is Playing Out
      seekingalpha.com •

    • Iveric Bio to Present at the UBS Global Healthcare Conference 2022
      businesswire.com •

    • IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q1 2022 Results - Earnings Call Transcript
      seekingalpha.com •

    • Wednesdays With Wedbush: 3 Smid-Cap Biotech Stock Picks
      benzinga.com •

    • Learning Lessons From 3 Stocks Flourishing In A Desperate Biotech Bear Market
      seekingalpha.com •

    • IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q4 2021 Results - Earnings Call Transcript
      seekingalpha.com •

    • IVERIC bio (ISEE) is on the Move, Here's Why the Trend Could be Sustainable
      zacks.com •

    • 7 A-Rated Biotechs to Buy for the Long Run
      investorplace.com •

    • IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q3 2021 Results - Earnings Call Transcript
      seekingalpha.com •

    • Apellis' Loss Is Iveric Bio's Gain In Lucrative Eye Disease Field
      seekingalpha.com •

    • ISEE Stock: Why It Significantly Increased Yesterday
      pulse2.com •

    • Iveric Bio to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
      businesswire.com •

    • Here's Why Iveric Bio Stock Is Rocketing Higher Today
      fool.com •

    • ISEE Stock: Why Rival Eye Drug Developer's Disappointment Is a Boon to IVERIC bio
      investorplace.com •

    • Why IVERIC Bio Shares Are Soaring Today
      benzinga.com •

    • Why Are Iveric Bio Shares Surging In Premarket Friday?
      benzinga.com •

    • New Strong Sell Stocks for August 18th
      zacks.com •

    • Implied Volatility Surging for IVERIC bio (ISEE) Stock Options
      zacks.com •

    • IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q2 2021 Results - Earnings Call Transcript
      seekingalpha.com •

    • Iveric Bio Reports Second Quarter 2021 Operational Highlights and Financial Results
      businesswire.com •

    • Iveric Bio Completes Patient Enrollment of GATHER2 Pivotal Clinical Trial of Zimura® Ahead of Schedule
      businesswire.com •

    • Small-Cap Stocks To Watch After CYTK Sheds Spotlight On Biotech
      pennystocks.com •

    • Iveric Bio Appoints Christopher Simms as Chief Commercial Officer
      businesswire.com •

    • IVERIC bio (ISEE) Enters Overbought Territory
      zacks.com •

    • Iveric Bio Raises $100M Via Equity To Fund Zimura Development In Geographic Atrophy
      benzinga.com •

    • IVERIC bio, Inc. Announces Pricing of $100 Million Public Offering of Common Stock
      businesswire.com •

    • IVERIC bio, Inc. Announces Proposed Offering of Common Stock
      businesswire.com •

    • Do Options Traders Know Something About IVERIC bio (ISEE) Stock We Don't?
      zacks.com •

    • IVERIC bio Stock Increased 11.87%: Why It Happened
      pulse2.com •

    • ISEE Stock Price Increases Over 30% Pre-Market: Why It Happened
      pulse2.com •

    • Iveric Bio Receives FDA Agreement Under Special Protocol Assessment (SPA) for GATHER2 Phase 3 Clinical Trial of Zimura® in Geographic Atrophy Secondary to Age-Related Macular Degeneration
      businesswire.com •

    • Iveric Bio Reveals Positive Post-Hoc Analyses Of Zimura In Dry Age-Related Macular Degeneration
      benzinga.com •

    • Iveric Bio to Present Zimura® GATHER2 Enrollment and Retention Updates and New GATHER1 Post-Hoc Analyses Today at its Dry Age-Related Macular Degeneration Virtual Symposium for Investors
      businesswire.com •

    • Iveric Bio to Host Investor Symposium on Dry Age-Related Macular Degeneration on June 18, 2021
      businesswire.com •

    • IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q1 2021 Results - Earnings Call Transcript
      seekingalpha.com •

    • New Strong Sell Stocks for April 26th
      zacks.com •

    • New Strong Sell Stocks for April 21st
      zacks.com •

    • New Strong Sell Stocks for April 6th
      zacks.com •

    • David R. Guyer, MD to Step Down from Iveric Bio Board to Rejoin Venture Fund
      businesswire.com •

    • Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
      businesswire.com •

    • IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q4 2020 Results - Earnings Call Transcript
      seekingalpha.com •

    • Iveric Bio Reports Fourth Quarter and Year End 2020 Operational Highlights and Financial Results
      businesswire.com •

    • Iveric Bio to Present at the Cowen 41st Annual Health Care Conference
      businesswire.com •

    • IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q3 2020 Results - Earnings Call Transcript
      seekingalpha.com •

    • 4 Health Stocks Stonepine Capital Loves (1 Has Gained 233% Since September 29)
      insidermonkey.com •

    • Europe Dry Age-Related Macular Degeneration Market and Competitive Landscape Report 2020 - ResearchAndMarkets.com
      businesswire.com •

    • Europe Wet Age-Related Macular Degeneration Market and Competitive Landscape Report 2020: Pipeline, Epidemiology, Market Valuations, Drug Sales, Market Forecast, Drug Forecasts, & Market Shares - ResearchAndMarkets.com
      businesswire.com •

    • IVERIC bio Reports Second Quarter 2020 Operational Highlights and Financial Results
      finance.yahoo.com •

    • IVERIC bio to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
      finance.yahoo.com •

    • World Retinal Biologics Market: Growth, Trends and Forecasts (2020-2025) - ResearchAndMarkets.com
      businesswire.com •

    • IVERIC bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
      finance.yahoo.com •

    • Worsening eye sight doesn't stop for Covid, neither did we
      irishtimes.com •

    • IVERIC bio to Report Second Quarter 2020 Financial Results and Host Conference Call on Wednesday, August 5, 2020
      finance.yahoo.com •

    • What You Need To Know About IVERIC bio, Inc.'s (NASDAQ:ISEE) Investor Composition
      finance.yahoo.com •

    • Did Hedge Funds Make The Right Call On IVERIC bio, Inc. (ISEE) ?
      finance.yahoo.com •

    • IVERIC bio Announces the Addition of Mark S. Blumenkranz, M.D., M.M.S., to its Board of Directors
      finance.yahoo.com •

    • Two Sigma Advisers LP Has $258,000 Stock Position in IVERIC bio Inc (NASDAQ:ISEE)
      thelincolnianonline.com •

    • 17,273 Shares in IVERIC bio Inc (NASDAQ:ISEE) Purchased by JPMorgan Chase & Co.
      thelincolnianonline.com •

    • Moving Average Crossover Alert: IVERIC bio
      finance.yahoo.com •

    • Iveric's Trial Progress And Other News: The Good, Bad And Ugly Of Biopharma
      seekingalpha.com •

    • Juvenile Macular Degeneration (JMD) Industry Report 2020: Overview of Therapeutic Pipeline Activity and Assessment of Products - ResearchAndMarkets.com
      businesswire.com •

    • IVERIC bio Announces First Patient Dosed in Second Zimura® Phase 3 Clinical Trial for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration
      finance.yahoo.com •

    • Iveric Bio: Pick Up Post-Fundraising Low And Hold For Good News
      seekingalpha.com •

    • Two Sigma Investments LP Invests $675,000 in IVERIC bio Inc (NASDAQ:ISEE)
      thelincolnianonline.com •

    • Regeneron Pharmaceuticals : to Vigorously Defend Allegations Related to Contributions to a Patient Assistance Charity in 2013 and Early 2014 | MarketScreener
      marketscreener.com •

    • 822,050 Shares in IVERIC bio Inc (NASDAQ:ISEE) Acquired by Deutsche Bank AG
      thelincolnianonline.com •

    • IVERIC bio, Inc. Announces Closing of Public Offering and Concurrent Private Placement with $160 Million in Gross Proceeds
      finance.yahoo.com •

    • NOVARTIS AG : Buy rating from Oddo | MarketScreener
      marketscreener.com •

    • Bayer : contributes an additional 50 million units of treatment to the World Federation of Hemophilia Humanitarian Aid Program | MarketScreener
      marketscreener.com •

    • Novartis : discontinues hydroxychloroquine clinical trial based on slow enrollment, remains committed to pandemic research efforts | MarketScreener
      marketscreener.com •

    • IVERIC bio Inc (NASDAQ:ISEE) Receives Consensus Rating of “Hold” from Analysts
      thelincolnianonline.com •

    • IVERIC bio, Inc. Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
      finance.yahoo.com •

    • IVERIC bio, Inc. Announces Proposed Offering of Common Stock and Pre-Funded Warrants and Concurrent Private Placement
      finance.yahoo.com •

    • Specsavers stores have reopened for eye tests across Cambridgeshire
      cambridge-news.co.uk •

    • Specsavers: England stores open for routine eye tests from today - what to expect
      express.co.uk •

    • Cowen & Co. Maintains a Buy Rating on IVERIC bio (ISEE) - Markets
      markets.co •

    • Novartis : Cosentyx receives FDA approval for new indication to treat active non-radiographic axial spondyloarthritis | MarketScreener
      marketscreener.com •

    • Is IVERIC bio, Inc. (ISEE) Going to Burn These Hedge Funds?
      finance.yahoo.com •

    • Novartis : manufactures and donates 27,000 units of hand sanitizer to New York State | MarketScreener
      marketscreener.com •

    • First post
      Last post
    0
    • Categories
    • Login

    • Don't have an account? Register

    • Login or register to search.
    Copyright © 2023 finabase.io